单位：[1]Graduate School, Beijing University of Chinese Medicine, Beijing, China[2]Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China
Capital's Funds for Health Improvement and Research [2018-2-4065]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81873396]; China-Japan Friendship Hospital
第一作者单位：[1]Graduate School, Beijing University of Chinese Medicine, Beijing, China[2]Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China
通讯作者：
通讯机构：[2]Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China[*1]China-Japan Friendship Hospital, 2 Yinghua Dongjie, Hepingli, Beijing 100029, People’s Republic of China
推荐引用方式(GB/T 7714)：
Zheng Shu-Yue,Duan Hua,Cui Hui-Juan.Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge[J].JAMA ONCOLOGY.2020,6(11):1813-1813.doi:10.1001/jamaoncol.2020.3946.
APA：
Zheng, Shu-Yue,Duan, Hua&Cui, Hui-Juan.(2020).Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge.JAMA ONCOLOGY,6,(11)
MLA：
Zheng, Shu-Yue,et al."Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge".JAMA ONCOLOGY 6..11(2020):1813-1813
医学